These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37064116)

  • 1. Comprehensive proteome, phosphoproteome and kinome characterization of luminal A breast cancer.
    Yang G; Zuo C; Lin Y; Zhou X; Wen P; Zhang C; Xiao H; Jiang M; Fujita M; Gao XD; Fu F
    Front Oncol; 2023; 13():1127446. PubMed ID: 37064116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
    Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
    BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry.
    Adachi Y; Asaga S; Kumamaru H; Kinugawa N; Sagara Y; Niikura N; Jinno H; Saji S; Toi M
    Breast Cancer Res Treat; 2023 Oct; 201(3):397-408. PubMed ID: 37479943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive lobular carcinoma: clinicopathological features and subtypes.
    Danzinger S; Hielscher N; Izsó M; Metzler J; Trinkl C; Pfeifer C; Tendl-Schulz K; Singer CF
    J Int Med Res; 2021 Jun; 49(6):3000605211017039. PubMed ID: 34187216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
    Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
    Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
    Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
    PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
    Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
    Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma.
    Engels CC; Fontein DB; Kuppen PJ; de Kruijf EM; Smit VT; Nortier JW; Liefers GJ; van de Velde CJ; Bastiaannet E
    Br J Cancer; 2014 Jul; 111(3):532-8. PubMed ID: 24937677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive Lobular Carcinoma Has Worse Outcome Compared with Invasive Ductal Carcinoma in Stage IV Breast Cancer with Bone-Only Metastasis.
    Luo Y; Ma A; Huang S; Yu Y
    Breast Care (Basel); 2022 Jun; 17(3):296-305. PubMed ID: 35949419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
    Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
    Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
    Ciriello G; Gatza ML; Beck AH; Wilkerson MD; Rhie SK; Pastore A; Zhang H; McLellan M; Yau C; Kandoth C; Bowlby R; Shen H; Hayat S; Fieldhouse R; Lester SC; Tse GM; Factor RE; Collins LC; Allison KH; Chen YY; Jensen K; Johnson NB; Oesterreich S; Mills GB; Cherniack AD; Robertson G; Benz C; Sander C; Laird PW; Hoadley KA; King TA; ; Perou CM
    Cell; 2015 Oct; 163(2):506-19. PubMed ID: 26451490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
    Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
    BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.
    Pramod N; Nigam A; Basree M; Mawalkar R; Mehra S; Shinde N; Tozbikian G; Williams N; Majumder S; Ramaswamy B
    Oncologist; 2021 Jun; 26(6):e943-e953. PubMed ID: 33641217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma.
    Gruel N; Lucchesi C; Raynal V; Rodrigues MJ; Pierron G; Goudefroye R; Cottu P; Reyal F; Sastre-Garau X; Fourquet A; Delattre O; Vincent-Salomon A
    Eur J Cancer; 2010 Sep; 46(13):2399-407. PubMed ID: 20570624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
    Ameli F; Rose IM; Masir N
    Asian Pac J Cancer Prev; 2015; 16(6):2385-90. PubMed ID: 25824769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
    Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
    Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.